JP2019519467A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019519467A5 JP2019519467A5 JP2018549808A JP2018549808A JP2019519467A5 JP 2019519467 A5 JP2019519467 A5 JP 2019519467A5 JP 2018549808 A JP2018549808 A JP 2018549808A JP 2018549808 A JP2018549808 A JP 2018549808A JP 2019519467 A5 JP2019519467 A5 JP 2019519467A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- compound
- cells
- tumor
- tumors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 20
- 210000004027 cell Anatomy 0.000 claims 16
- 229910052751 metal Inorganic materials 0.000 claims 8
- 239000002184 metal Substances 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 6
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 6
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 6
- 239000002738 chelating agent Substances 0.000 claims 5
- 230000002285 radioactive effect Effects 0.000 claims 4
- 208000023958 prostate neoplasm Diseases 0.000 claims 3
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 2
- 125000000732 arylene group Chemical group 0.000 claims 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N iso-quinoline Natural products C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 claims 2
- 150000002537 isoquinolines Chemical class 0.000 claims 2
- 125000005647 linker group Chemical group 0.000 claims 2
- 150000002739 metals Chemical class 0.000 claims 2
- 125000006239 protecting group Chemical group 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 2
- 150000003222 pyridines Chemical class 0.000 claims 2
- 229910052702 rhenium Inorganic materials 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 125000003107 substituted aryl group Chemical group 0.000 claims 2
- 150000003536 tetrazoles Chemical class 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010061968 Gastric neoplasm Diseases 0.000 claims 1
- 229910052689 Holmium Inorganic materials 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 229910052772 Samarium Inorganic materials 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 229910052782 aluminium Inorganic materials 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 229910052802 copper Inorganic materials 0.000 claims 1
- 229910052733 gallium Inorganic materials 0.000 claims 1
- 210000004602 germ cell Anatomy 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 229910052738 indium Inorganic materials 0.000 claims 1
- 229910052745 lead Inorganic materials 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000037841 lung tumor Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000017066 negative regulation of growth Effects 0.000 claims 1
- 208000025402 neoplasm of esophagus Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000028591 pheochromocytoma Diseases 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 229910052706 scandium Inorganic materials 0.000 claims 1
- 229910052727 yttrium Inorganic materials 0.000 claims 1
- 229910052726 zirconium Inorganic materials 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022077992A JP2022116028A (ja) | 2016-03-22 | 2022-05-11 | 前立腺がんの内部放射線療法のための前立腺特異的膜抗原を標的とした高親和性薬剤 |
| JP2024002743A JP2024050608A (ja) | 2016-03-22 | 2024-01-11 | 前立腺がんの内部放射線療法のための前立腺特異的膜抗原を標的とした高親和性薬剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662311697P | 2016-03-22 | 2016-03-22 | |
| US62/311,697 | 2016-03-22 | ||
| PCT/US2017/023508 WO2017165473A1 (en) | 2016-03-22 | 2017-03-22 | Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022077992A Division JP2022116028A (ja) | 2016-03-22 | 2022-05-11 | 前立腺がんの内部放射線療法のための前立腺特異的膜抗原を標的とした高親和性薬剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019519467A JP2019519467A (ja) | 2019-07-11 |
| JP2019519467A5 true JP2019519467A5 (enExample) | 2020-04-30 |
| JP7073270B2 JP7073270B2 (ja) | 2022-05-23 |
Family
ID=59899817
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018549808A Active JP7073270B2 (ja) | 2016-03-22 | 2017-03-22 | 前立腺がんの内部放射線療法のための前立腺特異的膜抗原を標的とした高親和性薬剤 |
| JP2022077992A Pending JP2022116028A (ja) | 2016-03-22 | 2022-05-11 | 前立腺がんの内部放射線療法のための前立腺特異的膜抗原を標的とした高親和性薬剤 |
| JP2024002743A Pending JP2024050608A (ja) | 2016-03-22 | 2024-01-11 | 前立腺がんの内部放射線療法のための前立腺特異的膜抗原を標的とした高親和性薬剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022077992A Pending JP2022116028A (ja) | 2016-03-22 | 2022-05-11 | 前立腺がんの内部放射線療法のための前立腺特異的膜抗原を標的とした高親和性薬剤 |
| JP2024002743A Pending JP2024050608A (ja) | 2016-03-22 | 2024-01-11 | 前立腺がんの内部放射線療法のための前立腺特異的膜抗原を標的とした高親和性薬剤 |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US11458213B2 (enExample) |
| EP (3) | EP3433238B1 (enExample) |
| JP (3) | JP7073270B2 (enExample) |
| KR (4) | KR20230147751A (enExample) |
| CN (3) | CN120172884A (enExample) |
| AU (1) | AU2017238181B2 (enExample) |
| BR (1) | BR112018069507A2 (enExample) |
| CA (1) | CA3018709A1 (enExample) |
| CL (1) | CL2018002683A1 (enExample) |
| CY (1) | CY1124487T1 (enExample) |
| DK (2) | DK3925952T3 (enExample) |
| ES (2) | ES2877572T3 (enExample) |
| FI (1) | FI3925952T3 (enExample) |
| HR (2) | HRP20240215T1 (enExample) |
| HU (2) | HUE055607T2 (enExample) |
| LT (2) | LT3433238T (enExample) |
| MX (1) | MX384823B (enExample) |
| PH (1) | PH12018502048A1 (enExample) |
| PL (2) | PL3925952T3 (enExample) |
| PT (2) | PT3925952T (enExample) |
| RS (2) | RS65188B1 (enExample) |
| RU (2) | RU2021115958A (enExample) |
| SA (1) | SA518400103B1 (enExample) |
| SI (2) | SI3433238T1 (enExample) |
| TR (1) | TR201813644T1 (enExample) |
| WO (1) | WO2017165473A1 (enExample) |
| ZA (1) | ZA201806389B (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109803973B (zh) | 2016-08-10 | 2022-05-24 | 癌靶技术有限责任公司 | 螯合psma抑制剂 |
| CN109982998A (zh) * | 2016-11-23 | 2019-07-05 | 癌靶技术有限责任公司 | 白蛋白结合psma抑制剂 |
| JP7162592B2 (ja) | 2016-12-14 | 2022-10-28 | パーデュー・リサーチ・ファウンデイション | 線維芽細胞活性化タンパク質（ｆａｐ）標的イメージングおよび治療 |
| EP3618867A4 (en) | 2017-05-02 | 2021-01-20 | Cornell University | METHODS AND REAGENTS FOR TUMOR TARGETING WITH IMPROVED EFFICIENCY AND REDUCED TOXICITY |
| WO2018222778A1 (en) * | 2017-05-30 | 2018-12-06 | The Johns Hopkins University | Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer |
| EP3494999A1 (en) * | 2017-12-11 | 2019-06-12 | Technische Universität München | Psma ligands for imaging and endoradiotherapy |
| EP3494998A1 (en) * | 2017-12-11 | 2019-06-12 | Technische Universität München | Glycosylated psma inhibitors for imaging and endoradiotherapy |
| CN116617421A (zh) * | 2017-12-11 | 2023-08-22 | 慕尼黑工业大学 | 用于诊断和/或治疗的药物组合物 |
| MX2020006112A (es) | 2017-12-13 | 2020-08-24 | Sciencons AS | Complejo que comprende un compuesto orientado a psma vinculado a un radionucleido de plomo o torio. |
| KR20250126870A (ko) * | 2018-02-06 | 2025-08-25 | 더 존스 홉킨스 유니버시티 | 암 방사선 치료를 위한 psma 표적 방사성 할로겐화 우레아-폴리아미노카복실레이트 |
| MX2020008271A (es) * | 2018-02-06 | 2020-11-09 | Univ Heidelberg | Inhibidor de fap. |
| CN112004812B (zh) * | 2018-03-30 | 2023-05-26 | 未来化学株式会社 | 用于前列腺癌的诊断和治疗的psma靶向的放射性药物 |
| AU2019287595B2 (en) | 2018-04-27 | 2024-10-31 | University Of Iowa Research Foundation | Compositions for chelating metals at low temperatures |
| US20210393809A1 (en) * | 2018-09-28 | 2021-12-23 | Universität Heidelbert | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of psma-expressing cancers |
| RU2697519C1 (ru) * | 2018-10-15 | 2019-08-15 | Общество с ограниченной ответственностью "Изварино Фарма" | Средство пептидной природы, включающее псма-связывающий лиганд на основе производного мочевины, способ его получения и применение для получения конъюгата с лекарственным и диагностическим агентом |
| WO2020139012A1 (ko) * | 2018-12-27 | 2020-07-02 | (주)퓨쳐켐 | 카르복시산이 도입된 psma-표적 화합물 및 그의 용도 |
| WO2021001362A1 (en) | 2019-07-02 | 2021-01-07 | Advanced Accelerator Applications (Italy) Srl | Prostate specific membrane antigen (psma) ligands and uses thereof |
| RU2713151C1 (ru) * | 2019-07-02 | 2020-02-04 | Общество с ограниченной ответственностью "Изварино Фарма" | Конъюгат флуоресцентного красителя с веществом пептидной природы, включающим псма-связывающий лиганд на основе производного мочевины для визуализации клеток, экспрессирующих псма, способ его получения и применения |
| CN114341118A (zh) * | 2019-07-02 | 2022-04-12 | 先进加速器应用意大利公司 | 前列腺特异性膜抗原(psma)配体及其用途 |
| RU2730507C1 (ru) * | 2019-08-27 | 2020-08-24 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | Соединение для диагностики опухолей, экспрессирующих псма, и композиция на его основе |
| JP2023523235A (ja) * | 2020-04-29 | 2023-06-02 | ノバルティス アーゲー | Ｐｓｍａ結合リガンドを放射標識するための方法及びそれらのキット |
| WO2022043556A1 (en) | 2020-08-31 | 2022-03-03 | Novartis Ag | Stable radiopharmaceutical composition |
| EP4204020A1 (en) | 2020-08-31 | 2023-07-05 | Advanced Accelerator Applications International S.A. | Method of treating psma-expressing cancers |
| WO2022043557A1 (en) | 2020-08-31 | 2022-03-03 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
| US20230406847A1 (en) | 2020-11-12 | 2023-12-21 | Abx Advanced Biochemical Compounds Gmbh | Ligands of prostate specific membrane antigen (psma) containing heteroaromatic linker building blocks |
| US20240010623A1 (en) | 2020-11-19 | 2024-01-11 | Novartis Ag | Synthesis of prostate specific membrane antigen (psma) ligands |
| MX2021005089A (es) * | 2021-04-30 | 2022-11-01 | Instituto Nac De Investigaciones Nucleares | Radiofarmacos basados en el acido ((r)-1-((6-hidrazinilnicotinoil) d-alanil)pirrolidin-2-il)boronico (hynic-ifap) para la deteccion de la sobreexpresion de la proteina de activacion de fibrolastos. |
| WO2022266499A1 (en) * | 2021-06-17 | 2022-12-22 | Mayo Foundation For Medical Education And Research | Methods and materials for combining biologics with multiple chelators |
| KR20230050552A (ko) * | 2021-10-07 | 2023-04-17 | (주)퓨쳐켐 | 가돌리늄 화합물 및 이를 포함하는 전립선암의 진단 및 치료용 약학적 조성물 |
| JP2025506001A (ja) | 2022-02-09 | 2025-03-05 | ノバルティス アーゲー | ２２５－アクチニウム標識錯体及びビスマス封鎖剤を含む医薬組成物 |
| KR20250127126A (ko) * | 2022-12-21 | 2025-08-26 | 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 | 복수의 킬레이트제와 생물학적 제제를 조합하기 위한 방법 및 재료 |
| WO2025022285A2 (en) | 2023-07-21 | 2025-01-30 | Novartis Ag | Psma-targeting radioligand treatment regimen |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2694266C (en) * | 2007-06-26 | 2016-06-14 | The Johns Hopkins University | Labeled inhibitors of prostate specific membrane antigen (psma), biological evaluation, and use as imaging agents |
| WO2009070302A1 (en) | 2007-11-30 | 2009-06-04 | The Johns Hopkins University | Prostate specific membrane antigen (psma) targeted nanoparticles for therapy of prostate cancer |
| RU2539584C2 (ru) | 2008-12-05 | 2015-01-20 | Моликьюлар Инсайт Фармасьютикалз, Инк. | Комплексы технеция и рения с бис(гетероарилами) и способы их применения |
| PL3964502T3 (pl) * | 2009-03-19 | 2024-10-28 | The Johns Hopkins University | Związki do kierunkowania w psma i ich zastosowania |
| PL2739316T3 (pl) * | 2011-08-05 | 2019-09-30 | Molecular Insight Pharmaceuticals, Inc. | Radioznakowane inhibitory antygenu błonowego specyficznego dla prostaty |
| WO2013082338A1 (en) | 2011-11-30 | 2013-06-06 | The Johns Hopkins University | Homomultivalent and heteromultivalent inhibitors of prostate specific membrane antigen (pmsa) and uses thereof |
| SG11201505477TA (en) * | 2013-01-14 | 2015-08-28 | Molecular Insight Pharm Inc | Triazine based radiopharmaceuticals and radioimaging agents |
| EP2862857A1 (en) * | 2013-10-18 | 2015-04-22 | Deutsches Krebsforschungszentrum | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| MY194484A (en) * | 2013-10-18 | 2022-11-30 | Deutsches Krebsforsch | Labeled Inhibitors of Prostate Specific Membrane Antigen (PSMA), Their use as Imaging Agents and Pharmaceutical Agents for the Treatment of Prostate Cancer |
| ES2743482T3 (es) | 2014-05-06 | 2020-02-19 | Univ Johns Hopkins | Inhibidores de PSMA marcados con metal/radiometal para obtención de imágenes dirigidas a PSMA y radioterapia |
| EP3183236B1 (en) | 2014-08-24 | 2022-04-20 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften | Method for the production of 18f-labeled active esters and their application exemplified by the preparation of a psma-specific pet-tracer |
| EP3212610B1 (en) * | 2014-10-30 | 2020-10-28 | Katholieke Universiteit Leuven | Methods for low temperature fluorine-18 radiolabeling of biomolecules |
| US11520472B2 (en) * | 2015-09-24 | 2022-12-06 | Mitutoyo Corporation | Inspection program editing environment including integrated alignment program planning and editing features |
| US10688200B2 (en) * | 2015-12-31 | 2020-06-23 | Five Eleven Pharma Inc. | Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy |
-
2017
- 2017-03-22 ES ES17771028T patent/ES2877572T3/es active Active
- 2017-03-22 EP EP17771028.2A patent/EP3433238B1/en active Active
- 2017-03-22 DK DK21177643.0T patent/DK3925952T3/da active
- 2017-03-22 HU HUE17771028A patent/HUE055607T2/hu unknown
- 2017-03-22 RU RU2021115958A patent/RU2021115958A/ru unknown
- 2017-03-22 TR TR2018/13644A patent/TR201813644T1/tr unknown
- 2017-03-22 CN CN202510305793.6A patent/CN120172884A/zh active Pending
- 2017-03-22 LT LTEPPCT/US2017/023508T patent/LT3433238T/lt unknown
- 2017-03-22 EP EP24153551.7A patent/EP4385981A1/en active Pending
- 2017-03-22 ES ES21177643T patent/ES2972148T3/es active Active
- 2017-03-22 PL PL21177643.0T patent/PL3925952T3/pl unknown
- 2017-03-22 JP JP2018549808A patent/JP7073270B2/ja active Active
- 2017-03-22 KR KR1020237034341A patent/KR20230147751A/ko not_active Ceased
- 2017-03-22 AU AU2017238181A patent/AU2017238181B2/en active Active
- 2017-03-22 KR KR1020187030310A patent/KR102396307B1/ko active Active
- 2017-03-22 MX MX2018011519A patent/MX384823B/es unknown
- 2017-03-22 PL PL17771028T patent/PL3433238T3/pl unknown
- 2017-03-22 RS RS20240205A patent/RS65188B1/sr unknown
- 2017-03-22 SI SI201730908T patent/SI3433238T1/sl unknown
- 2017-03-22 RU RU2018133693A patent/RU2749399C2/ru active
- 2017-03-22 DK DK17771028.2T patent/DK3433238T3/da active
- 2017-03-22 HU HUE21177643A patent/HUE065327T2/hu unknown
- 2017-03-22 US US16/087,395 patent/US11458213B2/en active Active
- 2017-03-22 KR KR1020227015010A patent/KR20220063298A/ko not_active Ceased
- 2017-03-22 PT PT211776430T patent/PT3925952T/pt unknown
- 2017-03-22 HR HRP20240215TT patent/HRP20240215T1/hr unknown
- 2017-03-22 BR BR112018069507A patent/BR112018069507A2/pt unknown
- 2017-03-22 CA CA3018709A patent/CA3018709A1/en active Pending
- 2017-03-22 CN CN202210306552.XA patent/CN114716387B/zh active Active
- 2017-03-22 FI FIEP21177643.0T patent/FI3925952T3/fi active
- 2017-03-22 PT PT177710282T patent/PT3433238T/pt unknown
- 2017-03-22 RS RS20211071A patent/RS62274B1/sr unknown
- 2017-03-22 KR KR1020257012794A patent/KR20250057132A/ko active Pending
- 2017-03-22 LT LTEP21177643.0T patent/LT3925952T/lt unknown
- 2017-03-22 CN CN201780031580.2A patent/CN109311827B/zh active Active
- 2017-03-22 WO PCT/US2017/023508 patent/WO2017165473A1/en not_active Ceased
- 2017-03-22 HR HRP20211386TT patent/HRP20211386T1/hr unknown
- 2017-03-22 SI SI201731477T patent/SI3925952T1/sl unknown
- 2017-03-22 EP EP21177643.0A patent/EP3925952B1/en active Active
-
2018
- 2018-09-21 CL CL2018002683A patent/CL2018002683A1/es unknown
- 2018-09-24 PH PH12018502048A patent/PH12018502048A1/en unknown
- 2018-09-25 ZA ZA2018/06389A patent/ZA201806389B/en unknown
- 2018-09-25 SA SA518400103A patent/SA518400103B1/ar unknown
-
2021
- 2021-09-13 CY CY20211100803T patent/CY1124487T1/el unknown
-
2022
- 2022-05-11 JP JP2022077992A patent/JP2022116028A/ja active Pending
- 2022-08-22 US US17/892,203 patent/US20230015736A1/en not_active Abandoned
-
2024
- 2024-01-11 JP JP2024002743A patent/JP2024050608A/ja active Pending
- 2024-12-13 US US18/979,841 patent/US20250195700A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019519467A5 (enExample) | ||
| RU2021115958A (ru) | Простатический специфический мембранный антиген-таргетные высокоаффинные средства для эндорадиотерапии рака предстательной железы | |
| JP2015531371A5 (enExample) | ||
| EP4473980A3 (en) | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of psma-expressing cancers | |
| JP2013521281A5 (enExample) | ||
| JP2010531304A5 (enExample) | ||
| JP2019513734A5 (enExample) | ||
| FI3917626T3 (fi) | Psma:ta sitova kaksimuotoinen radiomerkkiaine ja terapeuttinen aine | |
| JP2017537080A5 (enExample) | ||
| JP2017538677A5 (enExample) | ||
| RU2018100142A (ru) | Гетероциклические соединения, эффективные для ингибирования киназы | |
| JP2011515397A5 (enExample) | ||
| RU2012141590A (ru) | Соединения для лечения рака | |
| JP2008535902A5 (enExample) | ||
| JP2016503414A5 (enExample) | ||
| JP2016519062A5 (enExample) | ||
| JP2019529518A5 (enExample) | ||
| JP2017536344A5 (enExample) | ||
| RU2020102453A (ru) | Фармацевтические композиции | |
| JP2015512943A5 (enExample) | ||
| JP2011522889A5 (enExample) | ||
| JP2016512831A5 (enExample) | ||
| RU2011124894A (ru) | Триазолотиадиазоловый ингибитор протеинкиназы с-мет | |
| JP2017526662A5 (enExample) | ||
| JP2019534865A5 (enExample) |